MediciNova(MNOV)
LA JOLLA, CA
BiotechnologyFocus: Small Molecules
MediciNova is a life sciences company focused on Small Molecules.
RespiratoryNeurologyInfectious DiseasesOncologyMetabolic Diseases
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
MN-166
ALSClinical Trials (1)
NCT06743776Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS
N/AIbudilast 20mg
Methamphetamine-dependenceClinical Trials (1)
NCT01217970Safety Interaction Trial Ibudilast and Methamphetamine
Phase 1Phase 1
Clinical Trials (1)
NCT01551316Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 1MN-166
Healthy VolunteersClinical Trials (1)
NCT04054206Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers
Phase 1MN-166
Healthy VolunteersClinical Trials (1)
NCT03533387Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers
Phase 1Phase 1
Clinical Trials (1)
NCT01013142Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 1ibudilast
Amyotrophic Lateral SclerosisClinical Trials (1)
NCT02714036A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)
Phase 1/2MN-166
GlioblastomaClinical Trials (1)
NCT03782415Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
Phase 1/2MN-166
Opioid AbuseClinical Trials (1)
NCT01740414Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
Phase 2Dose Group 1
AsthmaClinical Trials (1)
NCT00683449Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma
Phase 2Ibudilast
Alcohol Use DisorderClinical Trials (1)
NCT03594435Ibudilast for the Treatment of Alcohol Use Disorder
Phase 2Phase 2
Clinical Trials (1)
NCT02681055Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
Phase 2Ibudilast
Pneumonia, ViralClinical Trials (1)
NCT04429555Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS
Phase 2Phase 2
Clinical Trials (1)
NCT01982942Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
Phase 2Phase 2
Clinical Trials (1)
NCT02238626Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Phase 2Phase 2
Clinical Trials (1)
NCT02503657Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis
Phase 2MN-221
AsthmaClinical Trials (1)
NCT00838591Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma
Phase 2Phase 2
Clinical Trials (1)
NCT05464784MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Phase 2MN-001 BID
Interstitial CystitisClinical Trials (1)
NCT00295854Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis
Phase 2MN-221
AsthmaClinical Trials (1)
NCT00679263Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma
Phase 2Phase 2/3
Clinical Trials (1)
NCT04057898Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
Phase 2/3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 21 clinical trials
SEC Filings: 2 available
Financials (FY2025)
Revenue
$410K59%
R&D Spend
$7M(1660%)28%
Net Income
-$11MCash
$40M